Skip to main content

Table 1

From: Clinical significance of hyperbilirubinemia in the CASTLE study

   Patients without hyperbilirubinemia Patients with hyperbilirubinemia
MOS-HIV Physical Summary Score Categories at Week 96    
  Improvement 76/138 (55%) 70/128 (55%)
  No change 35/138 (25%) 29/128 (23%)
  Worsening 27/138 (20%) 29/128 (23%)
MOS-HIV Mental Summary Score Categories at Week 96    
  Improvement 97/138 (70%) 92/128 (72%)
  No change 25/138 (18%) 18/128 (14%)
  Worsening 16/138 (12%) 18/128 (14%)
Adherence Through Week 96    
  To regimen 154/186 (83%) 147/176 (84%)
  To ATV 159/186 (85%) 153/176 (87%)